BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 07-Nov-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.

BXPHARMA 28-Oct-2018

There will be no price limit on the trading of the shares of the Company today (28.10.2018) following its corporate declaration.

BXPHARMA 28-Oct-2018

(Continuation news of BXPHARMA): The Company has also reported Consolidated EPS of Tk. 6.25, Consolidated NAV per share of Tk. 66.78 and Consolidated NOCFPS of Tk. 4.49 for the year ended on June 30, 2018. (end)

BXPHARMA 28-Oct-2018

The Board of Directors has recommended 12.50% cash dividend for the year ended on June 30, 2018. The Board has also decided to hold an EGM to pass Special Resolutions to amend certain Clauses of Memorandum of Association and Articles of Association of the Company. Date of EGM & AGM: 22.12.2018, Time for EGM & AGM: 10:00 AM & 10:30 AM respectively, Venue: Beximco Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date: 26.11.2018. (cont.)

BXPHARMA 18-Oct-2018

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 25, 2018 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.

BXPHARMA 08-Aug-2018

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA+" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2017, unaudited financials up to March 31, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

BXPHARMA 30-Apr-2018

(Q3 Un-audited): EPS was Tk. 1.49 for January-March 2018 as against Tk. 1.29 for January-March 2017; EPS was Tk. 4.74 for July 2017-March 2018 as against Tk. 4.03 for July 2016-March 2017. NOCFPS was Tk. 3.83 for July 2017-March 2018 as against Tk. 4.37 for July 2016-March 2017. NAV per share was Tk. 65.26 as on March 31, 2018 and Tk. 60.36 as on March 31, 2017.

BXPHARMA 23-Apr-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 26, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.

BXPHARMA 03-Apr-2018

(Continuation news of BXPHARMA): in hormones and steroid drugs, in terms of the decision of the shareholders of the company in its AGM and thus it completed the acquisition. The Government of Bangladesh currently holds 12.92% stake in Nuvista Pharma Limited. (end)

BXPHARMA 03-Apr-2018

Referring to their earlier news (disseminated by DSE on 08.10.2017) regarding acquiring a majority shareholding (85.22%) in Nuvista Pharma Ltd., the Company has further informed that the Board of Directors of the Company has considered and approved the acquisition of 10,013,474 ordinary shares of Tk. 10.00 each being 85.22% shareholdings of total capital in Nuvista Pharma Limited (formerly Organon Bangladesh Limited), a leading Pharma company in Bangladesh, specializing (cont.)

Previous Next page